[go: up one dir, main page]

WO2008133929A3 - Protéines miniatures perméables aux cellules - Google Patents

Protéines miniatures perméables aux cellules Download PDF

Info

Publication number
WO2008133929A3
WO2008133929A3 PCT/US2008/005264 US2008005264W WO2008133929A3 WO 2008133929 A3 WO2008133929 A3 WO 2008133929A3 US 2008005264 W US2008005264 W US 2008005264W WO 2008133929 A3 WO2008133929 A3 WO 2008133929A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
miniature
miniature proteins
app
permeable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/005264
Other languages
English (en)
Other versions
WO2008133929A2 (fr
Inventor
Alanna S Schepartz
Douglas S Daniels
Betsy Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2008133929A2 publication Critical patent/WO2008133929A2/fr
Publication of WO2008133929A3 publication Critical patent/WO2008133929A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de manière générale des protéines miniatures, notamment des protéines miniatures qui sont perméables aux cellules. Certains aspects de l'invention concernent de manière générale des protéines miniatures, par exemple le polypeptide pancréatique aviaire (aPP), modifiées de manière à ce que les protéines miniatures soient perméables aux cellules. Par exemple, une partie de l'aPP, telle que la région de l'hélice alpha et/ou la région de l'hélice de polyproline de type II, peut être modifiée pour rendre la région sensiblement cationique. Par exemple, un ou plusieurs résidus peuvent être substitués avec des résidus acides aminés cationiques tels que l'arginine. Les protéines miniatures peuvent également comporter des fonctions supplémentaires, par exemple la capacité à se lier à d'autres protéines telles que Bcl2 ou hDM2. Un autre aspect de l'invention concerne de manière générale des séquences, telles que PRR ou PPR, qui peuvent être ajoutées à d'autres protéines afin d'augmenter leur perméabilité aux cellules. D'autres aspects de l'invention concernent de manière générale des procédés de préparation de telles protéines, des procédés d'utilisation de telles protéines, des kits comprenant de telles protéines et analogues.
PCT/US2008/005264 2007-04-24 2008-04-24 Protéines miniatures perméables aux cellules Ceased WO2008133929A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US92637907P 2007-04-24 2007-04-24
US60/926,379 2007-04-24
US990508P 2008-01-03 2008-01-03
US61/009,905 2008-01-03
US1131108P 2008-01-16 2008-01-16
US61/011,311 2008-01-16
US6825908P 2008-03-05 2008-03-05
US61/068,259 2008-03-05

Publications (2)

Publication Number Publication Date
WO2008133929A2 WO2008133929A2 (fr) 2008-11-06
WO2008133929A3 true WO2008133929A3 (fr) 2008-12-24

Family

ID=39764715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005264 Ceased WO2008133929A2 (fr) 2007-04-24 2008-04-24 Protéines miniatures perméables aux cellules

Country Status (1)

Country Link
WO (1) WO2008133929A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818804B (zh) * 2019-10-21 2021-06-04 兰州大学 脑靶向肽及其在制备增强记忆药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169274A2 (fr) * 2013-04-12 2014-10-16 Yale University Protéines modifiées et leurs procédés d'utilisation
JP6495270B2 (ja) 2013-10-30 2019-04-03 ザ ユニバーシティ オブ ウェスタン オーストラリア 神経保護ペプチドを含有する医薬組成物
EP3145523A4 (fr) * 2014-05-21 2018-02-21 President and Fellows of Harvard College Peptides inhibiteurs de ras et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAESAR CHRISTINA E B ET AL: "Membrane interactions of cell-penetrating peptides probed by tryptophan fluorescence and dichroism techniques: Correlations of structure to cellular uptake", BIOCHEMISTRY, vol. 45, no. 24, June 2006 (2006-06-01), pages 7682 - 7692, XP002498266, ISSN: 0006-2960 *
CHIN J W ET AL: "Concerted evolution of structure and function in a MINIATURE PROTEIN", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC.; US, US, vol. 123, 28 March 2001 (2001-03-28), pages 2929 - 2930, XP002196758, ISSN: 0002-7863 *
DANIELS DOUGLAS S ET AL: "Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 28 NOV 2007, vol. 129, no. 47, 28 November 2007 (2007-11-28), pages 14578 - 14579, XP002498265, ISSN: 1520-5126 *
NIARCHOS ET AL: "Characterization of a novel cell penetrating peptide derived from Bag-1 protein", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 27, no. 11, 1 November 2006 (2006-11-01), pages 2661 - 2669, XP005713903, ISSN: 0196-9781 *
SADLER KRISTEN ET AL: "Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7.", BIOCHEMISTRY, vol. 41, no. 48, 3 December 2002 (2002-12-03), pages 14150 - 14157, XP002498267, ISSN: 0006-2960 *
SMITH BETSY A ET AL: "Minimally cationic cell-permeable miniature proteins via alpha-helical arginine display.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 12 MAR 2008, vol. 130, no. 10, 12 March 2008 (2008-03-12), pages 2948 - 2949, XP002498264, ISSN: 1520-5126 *
THOREN P E G ET AL: "Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 307, no. 1, 18 July 2003 (2003-07-18), pages 100 - 107, XP004434078, ISSN: 0006-291X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818804B (zh) * 2019-10-21 2021-06-04 兰州大学 脑靶向肽及其在制备增强记忆药物中的应用

Also Published As

Publication number Publication date
WO2008133929A2 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
WO2011097381A8 (fr) Enzymes génétiquement modifiées par des enzymes méthionine-gamma-lyase, et préparations pharmacologiques associées
NZ625630A (en) Human il-23 antigen binding proteins
WO2009149956A3 (fr) Protéine de fusion et son utilisation
ES2379283T3 (es) Proteínas de unión a albúmina sérica
WO2011020033A3 (fr) Protéines recombinées comprenant des domaines mutants de fibronectine
WO2010059424A3 (fr) Procédés et compositions pour dégrader un matériau cellulosique
WO2006136244A3 (fr) Utilisation de cellules souches stromales issues du tissu adipeux dans le traitement d'une fistule
UA101944C2 (ru) Композиции и способы применения для антител dickopf-1
WO2009137778A3 (fr) Procédés et compositions pour l'obtention de l'espèce clostridia par génie génétique
PL384263A1 (pl) Wariant oksydazy moczanowej i jego zastosowanie
WO2006105152A3 (fr) Compositions a base de cellules amniotiques, methodes de production et utilisations desdites compositions
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
ATE541283T1 (de) Verfahren zum mischen von farben in einem display
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
TW200640482A (en) Variant forms of urate oxidase and use thereof
WO2008083271A3 (fr) Procédés et compositions pour l'expression et la purification de protéines améliorées
WO2006116181A3 (fr) Proteines regulatrices mediatrices des lymphocytes t et leurs utilisations
WO2008112911A3 (fr) Réovirus atténués pour sélection de populations de cellules
WO2008133929A3 (fr) Protéines miniatures perméables aux cellules
WO2008157840A3 (fr) Peptides c-terminaux d'alpha connexine (act) pour traiter la dégénérescence maculaire liée à l'âge
DE602006016735D1 (de) Verfahren zur proliferation von stammzellen
HK1206763A1 (en) Charged nutritive fragments, proteins and methods
WO2005120215A8 (fr) Variantes shine de facteur de transcription et leur utilisation use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743230

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08743230

Country of ref document: EP

Kind code of ref document: A2